Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000084-16
    Sponsor's Protocol Code Number:NC-6004-004A
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-11-05
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-000084-16
    A.3Full title of the trial
    A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non-Small Cell Lung, Biliary Tract, and Bladder Cancer
    Sperimentazione di Fase 1b/2 di incremento graduale della dose ed espansione su NC-6004 (cisplatino in nanoparticelle) più gemcitabina in pazienti con tumori solidi in stadio avanzato o carcinoma polmonare non a piccole cellule squamoso, carcinoma delle vie biliari e carcinoma della vescica
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Medical Treatment of Advanced Solid Tumors or Squamous Non-Small Cell Lung, Biliary Tract, and Bladder Cancer
    Trattamento medico dei tumori solidi in stadio avanzato o carcinoma polmonare non a piccole cellule squamoso, carcinoma delle vie biliari e carcinoma della vescica
    A.3.2Name or abbreviated title of the trial where available
    -
    -
    A.4.1Sponsor's protocol code numberNC-6004-004A
    A.5.1ISRCTN (International Standard Randomised Controlled Trial) NumberISRCTN00000000
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT00000000
    A.5.3WHO Universal Trial Reference Number (UTRN)U0000-0000-0000
    A.5.4Other Identifiers
    Name:-Number:-
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNANOCARRIER CO, LIMITED
    B.1.3.4CountryJapan
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNanoCarrier Ltd
    B.4.2CountryJapan
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPPD, Inc.
    B.5.2Functional name of contact pointPeter Mascenik
    B.5.3 Address:
    B.5.3.1Street Address929 North Front Street
    B.5.3.2Town/ cityWilmington, N.Carolina
    B.5.3.3Post code28401-3331
    B.5.3.4CountryUnited States
    B.5.4Telephone number0019105588039
    B.5.5Fax number0019105588039
    B.5.6E-mailPeter.Mascenik@ppdi.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNanoparticle Cisplatin
    D.3.2Product code [NC-6004]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNanoparticle Cisplatin
    D.3.9.2Current sponsor codeNC-6004
    D.3.9.4EV Substance CodeSUB07483MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGemcitabina
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Powder and solvent for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGEMCITABINA CLORIDRATO
    D.3.9.2Current sponsor code-
    D.3.9.4EV Substance CodeSUB02324MIG
    D.3.10 Strength
    D.3.10.1Concentration unit g gram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Dexamethasone
    D.2.1.1.2Name of the Marketing Authorisation holderJENAPHARM®
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product name-
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDESAMETASONE
    D.3.9.1CAS number 50-02-2
    D.3.9.2Current sponsor code-
    D.3.9.4EV Substance Code-
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Diphenhydramine Hydrochloride
    D.2.1.1.2Name of the Marketing Authorisation holderWEST-WARD PHARMACEUTICALS
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product name-
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDIFENIDRAMINA CLORIDRATO
    D.3.9.1CAS number 58-73-1
    D.3.9.2Current sponsor code-
    D.3.10 Strength
    D.3.10.1Concentration unit mg/l milligram(s)/litre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Calmaben
    D.2.1.1.2Name of the Marketing Authorisation holderPharmazeutische Fabrik Montavit Ges.m.b.H.
    D.2.1.2Country which granted the Marketing AuthorisationAustria
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product name-
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDIFENIDRAMINA CLORIDRATO
    D.3.9.1CAS number 0000058-73-1
    D.3.9.2Current sponsor code-
    D.3.9.3Other descriptive name-
    D.3.9.4EV Substance Code-
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ranitidine HCl
    D.2.1.1.2Name of the Marketing Authorisation holderSOPHARMA AD
    D.2.1.2Country which granted the Marketing AuthorisationBulgaria
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product name-
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRANITIDINA CLORIDRATO
    D.3.9.1CAS number 66357-35-5
    D.3.9.2Current sponsor code-
    D.3.9.3Other descriptive name-
    D.3.9.4EV Substance Code-
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ranitidine Unipharm
    D.2.1.1.2Name of the Marketing Authorisation holderUNIPHARM AD
    D.2.1.2Country which granted the Marketing AuthorisationBulgaria
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product name-
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRANITIDINA
    D.3.9.1CAS number 66357-35-5
    D.3.9.2Current sponsor code-
    D.3.9.3Other descriptive name-
    D.3.9.4EV Substance Code-
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Advanced solid tumors and first-line metastatic squamous NSCLC; firstline metastatic or locally advanced cholangiocarcinoma, gallbladder cancer, or ampullary cancer (biliary tract cancer); and first-line metastatic or locally advanced transitional cell carcinoma (TCC) of the urinary tract (bladder cancer).
    Tumori solidi in stadio avanzato e NSCLC squamoso metastatico in terapia di prima linea; colangiocarcinoma, carcinoma della colecisti o carcinoma ampollare (carcinoma delle vie biliari) metastatico o localmente avanzato in terapia di prima linea; e carcinoma a cellule transizionali (TCC) delle vie urinarie (carcinoma della vescica) metastatico o localmente avanzato in terapia di prima linea
    E.1.1.1Medical condition in easily understood language
    Cancer of Lung, bladder cancer, biliary tract cancer, advanced solid tumors.
    Carcinoma del polmone, carcinoma della vescica, carcinoma delle vie biliari, tumori solidi in stadio avanzato.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10061873
    E.1.2Term Non-small cell lung cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10005003
    E.1.2Term Bladder cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10017614
    E.1.2Term Gallbladder cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    In the expansion phase of the study (Part 2), to evaluate the activity of NC-6004 in combination with gemcitabine in patients with first-line Stage IV squamous NSCLC, first-line advanced or metastatic biliary tract cancer, and first-line metastatic or locally advanced bladder cancer compared with historical control as measured by local investigator/radiologist-assessed progression-free survival (PFS), according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
    Nella fase di espansione dello studio (Parte 2), valutare l'attività di NC-6004 in combinazione con gemcitabina in pazienti con NSCLC squamoso di Stadio IV in terapia di prima linea, carcinoma delle vie biliari avanzato o metastatico in terapia di prima linea e carcinoma della vescica metastatico o localmente avanzato in terapia di prima linea rispetto al controllo storico, misurato in base alla sopravvivenza libera da progressione (PFS) valutata dallo sperimentatore/radiologo
    locale, secondo i criteri di valutazione della risposta nei tumori solidi (RECIST) versione 1.1.
    E.2.2Secondary objectives of the trial
    - To evaluate ORR, DCR (DCR = complete response [CR] + partial response [PR] + stable disease [SD]), DOR, PFS, and OS;
    - To evaluate therapy-related AEs;
    - To evaluate the safety and tolerability of NC-6004 when combined with gemcitabine;
    - To evaluate QoL using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQC30);
    - To evaluate acute and delayed symptoms using the MD Anderson Symptom Inventory (MDASI) and a nausea and vomiting patient diary.
    Valutare ORR, DCR (DCR = risposta completa [CR] + risposta parziale [PR] + malattia stabile [SD]), DOR, PFS, e OS;
    - Valutare gli eventi avversi (AE) correlati alla terapia;
    - Valutare la sicurezza e la tollerabilità di NC-6004 in associazione con gemcitabina
    - Valutare la qualità di vita utilizzando il questionario principale di misurazione della qualità di vita redatto dall'Organizzazione europea per la ricerca e il trattamento del cancro (EORTC QLQ-C30)
    - Valutare i sintomi acuti e ritardati utilizzando il questionario di valutazione dei sintomi MDASI (MD Anderson Symptom Inventory) e un diario del paziente relativo a nausea e vomito
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Provide signed written informed consent prior to the initiation of any study-specific procedures.
    2.Cohort 1: Have histologically or cytologically confirmed diagnosis of Stage IV squamous NSCLC and have not received prior chemotherapy or immunotherapy for metastatic disease and are not known to be PD-L1
    positive. Patients with known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) fusion oncogene must have received at least 1 and up to 2 targeted therapies prior to enrollment.
    - A patient with stable, treated brain metastases is eligible, provided that there is no evidence of progression after treatment and the patient does not require corticosteroids, or, if the patient requires corticosteroid, has been receiving a stable dose of corticosteroids for at least 14 days prior to
    assignment to treatment.
    - A patient with stable, treated brain metastases is eligible, provided that there is no evidence of progression after treatment and the patient does not require corticosteroids, or, if the patient requires corticosteroid, has been receiving a stable dose of corticosteroids for at least 14 days prior to assignment to treatment.
    - Patients whose tumors are known to harbor an exon 19 deletion or exon 21 L858R EGFR mutation must have had intolerance or have progressed on at least 1 and up to 2 EGFR tyrosine kinase inhibitors.
    - Patients whose tumors are known to harbor an ALK translocation must have had intolerance or have progressed on at least 1 and up to 2 ALK inhibitors.
    (Part 2 only) Cohort 2: Have histologically or cytologically confirmed diagnosis of nonresectable, recurrent, or metastatic biliary
    tract carcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) and have not
    received prior systemic anticancer therapy for advanced or metastatic disease. (Part 2 only) Cohort 3: Have histologically or
    cytologically confirmed diagnosis of metastatic or locally advanced TCC of the urinary tract (bladder, urethra, ureter, renal pelvis)
    (T3b-T4 N0 M0, Tany N1-N3 M0, or Tany Nany M1)
    and are not candidates for surgery.
    - Patients must not have received prior treatment with systemic anticancer therapy for metastatic or locally advanced urinary tract
    cancer.
    - Certain mixed histologies that are predominantly (>50%) TCC are eligible: squamous, adenocarcinoma, and undifferentiated.
    Mixed
    undifferentiated histology requires immunohistochemistry consistent with a TCC origin. Predominantly squamous or
    neuroendocrine tumors
    are excluded.
    3. Have measurable disease per RECIST version 1.1.
    4. Are males or females aged =18 years.
    5. Have an ECOG performance status of 0 to 1.
    6. Have adequate bone marrow reserve defined as:
    - Absolute neutrophil count of at least 1.5 × 109/L,
    - Platelet count of at least 100 × 109/L, and
    - Hemoglobin level of 10 g/dL (transfusion is allowed to achieve
    hemoglobin
    level of at least 10 g/dL).
    7.Have adequate liver function defined as:
    - Total serum bilirubin <1.5 × upper limit of normal (ULN) and
    - Baseline alanine transaminase, and aspartate transaminase <2.0 × ULN or, in patients with documented hepatic metastasis =5.0 × ULN and Serum albumin =3.5 g/dL.
    8. Prothrombin time within normal limits
    9.Have a negative pregnancy test result at screening (for females of childbearing potential; not applicable to patients who are unable to become pregnant, including those with bilateral oophorectomy and/or hysterectomy or postmenopausal [no menses for the previous 12 months]). The test must be performed within 1 week before Day 1 of treatment.
    10.Male patients must agree to use a condom during treatment and for 90 days after dosing. Male patients must agree not to donate sperm for 90 days after dosing.
    11.For women of childbearing potential*: are willing to follow 1 of the following effective methods of birth control from the time of study entry to 6 months after the last day of treatment:
    1.Fornire il consenso informato scritto prima dell'inizio
    2.Coorte 1: Presentare una diagnosi confermata a livello istologico o citologico di NSCLC squamoso di Stadio IV e non aver ricevuto precedente chemioterapia per malattia metastatica. I pazienti con una nota mutazione sensibilizzante del gene del recettore del fattore di crescita epidermico (EGFR) o dell'oncogene di fusione della chinasi del linfoma anaplastico (ALK) devono aver ricevuto almeno 1 e un massimo di 2 terapie mirate prima dell'arruolamento.
    - Un paziente con metastasi cerebrali trattate e stabili è eleggibile a condizione che non presenti evidenze di progressione dopo il trattamento e non abbia necessità di assumere corticosteroidi o, se il paziente necessita di corticosteroidi, abbia assunto una dose stabile di corticosteroidi per almeno 14 giorni prima dell'assegnazione al trattamento.
    - I pazienti i cui tumori sono noti per essere portatori di una delezione nell'esone 19 o di una mutazione L858R nell'esone 21 di EGFR devono aver manifestato intolleranza o avere avuto una progressione con almeno 1 e un massimo di 2 inibitori della tirosinchinasi dell'EGFR
    - I pazienti i cui tumori sono noti per essere portatori di una traslocazione dell'ALK devono aver manifestato intolleranza o avere avuto una progressione con almeno 1 e un massimo di 2 inibitori dell'ALK. (Solo parte 2) Coorte 2: Presentare una diagnosi confermata a livello istologico o citologico di carcinoma non resecabile, ricorrente o metastatico delle vie biliari (colangiocarcinoma intraepatico o extraepatico, carcinoma della colecisti o carcinoma ampollare) e non aver ricevuto precedente terapia anticancro sistemica per malattia avanzata o metastatica. (Solo parte 2) Coorte 3: Presentare una diagnosi confermata a livello istologico o citologico di TCC delle vie urinarie (vescica, uretra, uretere, pelvi renale) metastatico o localmente avanzato (T3b-T4 N0 M0, Tqualsiasi N1-N3 M0 o Tqualsiasi Nqualsiasi M1) e non essere candidati per intervento chirurgico.
    - I pazienti non devono aver ricevuto precedente trattamento con terapia anticancro sistemica per il carcinoma delle vie urinarie metastatico o localmente avanzato.
    - Sono eleggibili alcune istologie miste che siano prevalentemente (> 50%) di TCC: carcinoma squamoso, adenocarcinoma e carcinoma indifferenziato. L'istologia mista indifferenziata richiede immunoistochimica coerente con un'origine TCC. Sono esclusi i tumori a prevalenza squamosa o neuroendocrini.
    3.Presentare malattia misurabile in base ai criteri RECIST versione 1.1.
    4.Uomini o donne di età > 18
    5.Avere un PS secondo la scala dell'Eastern Cooperative Oncology Group (ECOG) da 0 a 1
    6.Presentare una riserva di midollo osseo adeguata, definita come:
    •Conta assoluta dei neutrofili di almeno 1,5 × 109/L
    •Conta piastrinica di almeno 100 × 109/L, e
    •Livello di emoglobina di almeno 10 g/dL (per ottenere un livello di emoglobina di almeno 10 g/dL è consentita la trasfusione).
    7.Presentare una funzione epatica adeguata, definita come:
    -Bilirubina sierica totale < 1,5 × limite superiore della norma (ULN)
    - Alla baseline, alanina transaminasi e aspartato transaminasi <2,0 × ULN o, in pazienti con metastasi epatiche documentate, =5,0 × ULN e albumina sierica =3,5 g/dl.
    8. Tempo di protrombina entro i limiti della norma
    9.Presentare un test di gravidanza negativo allo screening . Il test deve essere eseguito nell'arco di 1 settimana prima del Giorno 1 di trattamento.
    10.I pazienti di sesso maschile devono accettare di usare un preservativo durante il trattamento e per 90 giorni dopo il periodo di dosaggio. I pazienti di sesso maschile devono accettare di non donare sperma per 90 giorni dopo il periodo di dosaggio.
    11.Per le donne in età fertile*: essere disposte a seguire 1 dei seguenti metodi contraccettivi efficaci dal momento dell'ingresso nello studio fino a 6 mesi dopo l'ultimo giorno di trattamento:
    E.4Principal exclusion criteria
    1. Have received prior platinum therapy in the past 3 months (Part 1) or 6 months in the adjuvant or neoadjuvant setting (Part 2).
    2. Have received prior cisplatin and gemcitabine concomitantly within the last 6 months or are refractory to cisplatin and
    gemcitabine.
    3. Are unable to receive platinum-based therapy due to previous toxicity.
    4. Have unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment,
    with the exception of alopecia and =Grade 1 peripheral neuropathy according to the National Cancer Institute Common
    Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 (National Cancer Institute 2010).
    Clinical judgment by the investigator is allowed to determine if Grade 1 fatigue at screening is residual toxicity from prior
    treatment or is a symptom of the
    patient's general condition or disease. The investigator and Medical Monitor will discuss the eligibility of patients with baseline
    toxicity
    5. Have evidence suggesting pulmonary fibrosis or interstitial pneumonia.
    6. Have a history of thrombocytopenia with complications including hemorrhage or bleeding of =Grade 2 according to the NCI
    CTCAE version
    XML File Identifier: tPlPZ5rSiOxuu1wqhkLYhtuhz2U=
    Page 17/27 4.03 that required medical intervention or have any hemolytic condition or coagulation disorders that would make
    participation unsafe in the opinion of the investigator.
    7. Have known hypersensitivity to platinum compounds or gemcitabine.
    8. Have uncontrolled diabetes or have hypertension requiring more than 3 medications for control of hypertension.
    9.Have known active hepatitis B (defined as a known positive hepatitis B surface antigen [HBsAg] result) or hepatitis C (defined by a known positive hepatitis C
    antibody result or known quantitative HCV RNA results greater than the lower limits of detection of the
    assay).
    10. Have signs or symptoms of organ failure, major chronic illnesses other than cancer, or any concomitant medical or social
    conditions that,
    in the opinion of the investigator, make it undesirable for the patient to participate in the study or that could jeopardize
    compliance with the protocol.
    11. Have experienced any of the following within the 6-month period prior to screening:
    angina pectoris, coronary artery disease or cerebrovascular accident, transient ischemic attack, cardiac failure with known ejection
    fraction less than 40%, or cardiac arrhythmia requiring medical therapy.
    12. Are unwilling or unable to comply with study procedures or are planning to take a vacation for 7 or more consecutive days
    during the treatment phase of the study without prior consent from the Medical Monitor.
    1. Aver ricevuto una terapia a base di platino nei 3 mesi (Parte 1) o nei 6 mesi precedenti nel contesto di terapia adiuvante o neoadiuvante (Parte 2).
    2.Aver ricevuto cisplatino e gemcitabina in concomitanza nei 6 mesi precedenti o essere refrattari a cisplatino e gemcitabina.
    3.Non essere in grado di ricevere terapie a base di platino a causa di tossicità precedente.
    4.4. Presentare tossicità non risolte conseguenti a una precedente radioterapia, chemioterapia o altro trattamento mirato, compreso il trattamento sperimentale, con l'eccezione dell'alopecia e della neuropatia periferica di Grado = 1 secondo i criteri terminologici comuni per gli eventi avversi del National Cancer Institute (NCI CTCAE) versione 4.03. È consentito avvalersi del giudizio clinico dello sperimentatore per stabilire se l'affaticamento di Grado 1 allo screening sia una tossicità residua conseguente a un precedente trattamento o un sintomo delle condizioni generali o di malattia del paziente. Lo sperimentatore e il medical monitor analizzeranno l'eleggibilità dei pazienti con tossicità al basale.
    5.Presentare evidenze che suggeriscano fibrosi polmonare o polmonite interstiziale.
    6.Presentare un’anamnesi di trombocitopenia con complicanze che includano emorragia o sanguinamento di Grado >2 in base ai criteri NCI CTCAE versione 4.03 che hanno richiesto intervento medico o presentare qualsiasi patologia emolitica o disturbo della coagulazione che renderebbero non sicura la partecipazione secondo il parere dello sperimentatore.
    7.Presentare ipersensibilità nota ai composti del platino o alla gemcitabina.
    8.Presentare diabete non controllato o ipertensione che richiede più di 3 farmaci per il controllo dell'ipertensione.
    9.Presentare nota epatite B attiva (definita come risultato positivo noto dei test dell’antigene di superficie dell’epatite B [HBsAg]) o epatite C (definita come risultato positivo noto per l’anticorpo anti-epatite C o risultati noti del test HCV RNA quantitativo superiori ai limiti inferiori di rilevabilità per il saggio).
    10.Presentare segni o sintomi di insufficienza d’organo, malattie croniche importanti diverse dal cancro o qualsiasi condizione concomitante medica o sociale che, secondo il parere dello sperimentatore, renda non auspicabile per il paziente partecipare allo studio o che potrebbe mettere a rischio l'aderenza al protocollo.
    11.Aver manifestato uno dei seguenti eventi nei 6 mesi precedenti allo screening:
    angina pectoris, arteriopatia coronarica, accidente cerebrovascolare, attacco ischemico transitorio, insufficienza cardiaca con frazione di eiezione nota inferiore al 40% o aritmia cardiaca che richiede terapia medica.
    12.Non essere intenzionati o in grado di attenersi alle procedure dello studio oppure prevedere di assentarsi per 7 o più giorni
    consecutivi durante la fase di trattamento dello studio senza il previo consenso del medical monitor.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint progression-free survival (PFS), according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. will be continuously updated and compared with the historical PFS from Phase 3 pivotal cisplatin and gemcitabine trials within each cohort. The PFS hazard model will be updated as PFS data accrue. A hazard ratio (HR) for PFS for each cohort versus historical control will be obtained.
    L'endpoint primario di sopravvivenza libera da progressione (PFS), In base ai criteri di valutazione della risposta nei tumori solidi (RECIST) versione 1.1. sarà continuamente aggiornato e messo a confronto con i valori anamnestici di PFS dagli studi cardine di Fase 3 con cisplatino e gemcitabina in ciascuna coorte. Il modello di rischio per la PFS sarà aggiornato
    a mano a mano che saranno accumulati dati sulla PFS. Verrà ottenuto un rapporto di rischio (HR) per la PFS per ciascuna coorte rispetto al controllo storico.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Progression-free survival will be defined as the time from first dose of study product until the first date of either disease progression or death due to any cause and will be evaluated for each dose level and for all patients in the FAS. The date of disease progression will be defined as the earliest date of radiological disease progression as assessed by the investigator using RECIST version 1.1 or clinical disease progression. For patients who have not progressed or died at the time of the analysis, censoring will be performed using the date of the last adequate disease assessment. Once 10 PFS events have been observed, interim analyses will be performed every 6 weeks. At each interim and at the final analysis, there are 3 possible outcomes for each cohort.
    La sopravvivenza libera da progressione sarà definita come il periodo di tempo dalla prima dose di prodotto in studio fino alla prima data di progressione della malattia o decesso per qualsiasi causa e sarà valutata per ciascun livello di dosaggio e per tutti i pazienti nel gruppo FAS. La data di progressione della malattia sarà definita come la prima data di progressione della malattia evidenziata con esame radiologico valutata dallo sperimentatore usando RECIST versione 1.1 o progressione clinica della malattia. Per i pazienti che non hanno evidenziato progressione o erano deceduti al momento dell'analisi, sarà eseguita la censura usando la data dell'ultima valutazione adeguata della malattia. Una volta osservati 10 eventi di PFS, saranno eseguite analisi ad interim ogni 6 settimane.
    E.5.2Secondary end point(s)
    The exploratory endpoints of this study
    include exploratory safety endpoints of the occurrence of AEs and SAEs after 6 cycles of treatment and the following PK endpoints
    for micellar platinum in plasma and total
    platinum in plasma and plasma ultrafiltrate calculated for all patients using noncompartmental analysis:
    Cmax (maximum concentration)
    Tmax (time to maximum concentration)
    AUClast (area under the concentration-time curve from time zero to the last quantifiable oncentration)
    AUC0-t (area under the concentration-time curve from time zero to the end of the dosing interval)
    AUC0-8 (area under the concentration-time curve from time zero to infinity)
    AI (accumulation index)
    Vss (volume of distribution at steady-state)
    MRT (mean residence time)
    ¿z (terminal elimination phase rate constant)
    T½ (terminal half-life)
    CL (clearance)
    Vz (volume of distribution)
    - Safety endpoints:
    The safety endpoints for this study are the incidence and severity of AEs and laboratory abnormalities, according to the NCI CTCAE
    version 4.03, the occurrence of SAEs and treatment discontinuations due to AEs, and nausea severity and vomiting incidence obtained from the patient diary.
    - Efficasy analysis.
    Gli endpoint esplorativi di questo studio includono endpoint di sicurezza esplorativi relativi a manifestazione di AE e SAE dopo 6 cicli di trattamento e i seguenti endpoint di PK per platino micellare nel plasma e quantità totale di platino nel plasma e ultrafiltrato plasmatico calcolato per tutti i pazienti usando l’analisi non ompartimentale:
    Cmax (concentrazione massima)
    Tmax (tempo alla concentrazione massima)
    AUClast (area sotto la curva oncentrazione-tempo dal tempo zero fino all'ultima concentrazione quantificabile)
    AUCO-T (area sotto la curva oncentrazione-tempo dal tempo zero fino al termine dell'intervallo di dosaggio)
    AUCO-O (Area sotto la curva oncentrazione-tempo dal tempo zero all’infinito)
    Al (indice di accumulo)
    Vss (Volume di distribuzione allo steady state)
    MRT (tempo di residenza medio)
    ¿z (costante di velocità in fase di eliminazione terminale)
    TV½ (emivita terminale)
    CL (clearance)
    Vz (volume di distribuzione)
    -Endpoint di sicurezza:
    Gli endpoint di sicurezza per questo studio sono incidenza e severità di AE e anomalie di laboratorio, in conformità ai NCI CTCAE versione 4.03, manifestazione di SAE e interruzioni del trattamento dovute ad AE; e gravità della nausea e incidenza del vomito ottenuto dal diario del paziente.
    -Analisi dell'efficacia
    E.5.2.1Timepoint(s) of evaluation of this end point
    Pharmacokinetic plasma and plasma ultrafiltrate will be collected at the following times in Part 2 for up to 6 cycles:
    • Before the start of the NC-6004 infusion on Day 1
    • At the end of NC-6004 infusion
    • Before gemcitabine infusion on Day 8
    • At End-of-Treatment visit Adverse events will be evaluated at each visit during every cycle and graded according to the NCI CTCAE.
    Disease response assessment will occur every 6 weeks until disease progression.
    Quality of life will be assessed before treatment on Day 1 and Day 8 of each cycle and at the End-of-Treatment visit using the EORTC QLQ-C30.
    Symptoms will be assessed before treatment on Day 1 and Day 8 of each cycle and at the End-of-Treatment visit using the core MD Anderson Symptom Inventory
    I campioni di plasma e ultrafiltrato plasmatico per l'analisi farmacocinetica saranno prelevati nei seguenti punti temporali della Parte 2 per un massimo di 6 cicli:
    •Prima dell'inizio dell'infusione di NC-6004 il Giorno 1
    •Al termine dell'infusione di NC-6004
    •Prima dell'infusione di gemcitabina il Giorno 8
    •Alla visita di Fine trattamento
    Gli eventi avversi saranno valutati a ogni visita durante ogni ciclo e classificati in base ai criteri NCI CTCAE.
    La valutazione di risposta della malattia ogni 6 settimane fino a progressione della malattia.
    La qualità di vita valutata prima del trattamento il Giorno 1 e il Giorno 8 di ogni ciclo e alla visita di Fine trattamento. I sintomi valutati prima del trattamento il Giorno 1 e il Giorno 8 di ogni ciclo e alla visita di Fine trattamento
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    -
    Studio di fase I completato, l'Italia partecipa alla fase II.
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA12
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Bulgaria
    Italy
    Poland
    Romania
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LPLV
    LPLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days15
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days15
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 125
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 35
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 56
    F.4.2.2In the whole clinical trial 160
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-10-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-10-26
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 04:59:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA